Program
fingolimod
Also written as “Fingolimod”, “FTY720” and “Fingolimod 0.5 mg”.
Its studies are mostly in Multiple Sclerosis · Multiple Sclerosis, Relapsing-Remitting · Renal Insufficiency · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Multiple Sclerosis, Chronic Progressive, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 502 open or running | phase 4since Sep 7, 2010 | Dec 7, 2004 | none ahead |
| Alembic Pharmaceuticals | 10 open or running | phase 1since Nov 23, 2015 | Nov 23, 2015 | none ahead |
| Asofarma S.A.I. y C. | 10 open or running | phase 1since Nov 27, 2018 | Nov 27, 2018 | none ahead |
| Genuine Research Center, Egypt | 10 open or running | phase 1since Dec 2, 2020 | Dec 2, 2020 | none ahead |
Also a collaborator on its studies: Hikma Pharmaceuticals, zenith-technology-corporation-limited and Tanabe Pharma.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 39 studies since Dec 7, 2004.
- Aug 13, 2012Phase 4 study in Multiple SclerosisNovartis · NCT01705236 · 87 enrolled · Germany, Switzerland
- Dec 21, 2012Phase 2 study in Optic NeuritisNovartis · NCT01757691 · 2 enrolled · United States, Spain
- Feb 12, 2013Phase 2 study in UveitisNovartis · NCT01791192
- May 8, 2013Phase 3 study in Multiple SclerosisNovartis · NCT01892722 · 240 enrolled · United States, Australia, Austria and more
- Sep 9, 2013Phase 3 study in Multiple Sclerosis, Relapsing-RemittingNovartis · NCT01941004
- Sep 2, 2014Phase 4 study in Multiple SclerosisNovartis · NCT02232061 · 6 enrolled · Belgium, Germany, Italy
- Feb 4, 2015Phase 4 study in Multiple Sclerosis, Relapsing-RemittingNovartis · NCT02373098 · 126 enrolled · Turkey (Türkiye)
- Nov 23, 2015Alembic Pharmaceuticals's first study: phase 1 study in BioequivalenceNew to Alembic PharmaceuticalsAlembic Pharmaceuticals · NCT05145621 · 26 enrolled · Canada
- Mar 21, 2016Phase 4 study in Multiple Sclerosis, Relapsing-RemittingNovartis · NCT02720107 · 133 enrolled · Germany
- Aug 18, 2017Phase 4 study in Multiple SclerosisNovartis · NCT03257358 · 382 enrolled · United States
- Nov 27, 2018Asofarma S.A.I. y C.'s first study: phase 1 study in Healthy VolunteersNew to Asofarma S.A.I. y C.Asofarma S.A.I. y C. · NCT03757338 · 33 enrolled · New Zealand
- Jul 17, 2020Phase 4 study in Multiple SclerosisNovartis · NCT04480853 · 14 enrolled · Taiwan
- Dec 2, 2020Genuine Research Center, Egypt's first study: phase 1 study in HealthyNew to Genuine Research Center, EgyptGenuine Research Center, Egypt · NCT04657744 · 34 enrolled · Egypt
- Dec 8, 2020Phase 4 study in Relapsing Multiple Sclerosis (RMS)Novartis · NCT04667949 · 98 enrolled · China
TargetBeta
“The hydrochloride salt form of fingolimod, an orally available derivate of myriocin and sphingosine-1-phosphate receptor 1 (S1PR1, S1P1) modulator, ”NCIt, by rule
“Sphingosine 1-phosphate receptor agonist; Sphingosine 1-phosphate receptor binding agent”ChEMBL 37, by rule
Studies
All 53 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT04667949Relapsing Multiple Sclerosis (RMS) · China | 4 | Completed | Novartis | Mar 25, 2025 | 98 |
| NCT04657744Healthy · Egypt | 1 | Completed | Genuine Research Center, Egypt | Sep 28, 2020 | 34 |
| NCT04480853Multiple Sclerosis · Taiwan | 4 | Active, not recruiting | Novartis | Oct 15, 2026 | 14 |
| NCT03757338Healthy Volunteers · New Zealand | 1 | Completed | Asofarma S.A.I. y C. | Jan 26, 2016 | 33 |
| NCT03257358Multiple Sclerosis · United States | 4 | Completed | Novartis | Mar 5, 2019 | 382 |
| NCT02720107Multiple Sclerosis, Relapsing-Remitting · Germany | 4 | Completed | Novartis | Nov 14, 2016 | 133 |
| NCT05145621Bioequivalence · Canada | 1 | Completed | Alembic Pharmaceuticals | Jan 15, 2016 | 26 |
| NCT02373098Multiple Sclerosis, Relapsing-Remitting · Turkey (Türkiye) | 4 | Completed | Novartis | Jan 18, 2017 | 126 |
| NCT02232061Multiple Sclerosis · Belgium, Germany, Italy | 4 | Completed | Novartis | Jan 24, 2020 | 6 |
| NCT01941004Multiple Sclerosis, Relapsing-Remitting | 3 | Withdrawn | Novartis | May 2017 | 0 |
| NCT01892722Multiple Sclerosis · United States, Australia, Austria and more | 3 | Active, not recruiting | Novartis | Jul 14, 2017 | 240 |
| NCT01791192Uveitis | 2 | Withdrawn | Novartis | Oct 2014 | 0 |
| NCT01757691Optic Neuritis · United States, Spain | 2 | Terminated | Novartis | May 2014 | 2 |
| NCT01705236Multiple Sclerosis · Germany, Switzerland | 4 | Completed | Novartis | Feb 18, 2019 | 87 |
| NCT01633112Multiple Sclerosis, Relapsing-Remitting · United States, Argentina, Brazil and more | 3 | Terminated | Novartis | Apr 30, 2018 | 1,064 |
| NCT01625182Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Australia, Belgium and more | 3 | Completed | Novartis | Sep 3, 2016 | 106 |
| NCT01623596Multiple Sclerosis, Relapsing-Remitting · United States, Puerto Rico | 4 | Completed | Novartis | Jul 13, 2015 | 881 |
| NCT01621269Multiple Sclerosis | 4 | Withdrawn | Novartis | Jun 2014 | 0 |
| NCT01585298Multiple Sclerosis · Germany | 4 | Completed | Novartis | Dec 12, 2016 | 6,998 |
| NCT01578330Multiple Sclerosis · Turkey | 4 | Completed | Novartis | Apr 2015 | 42 |
| NCT01534182Multiple Sclerosis, Relapsing-Remitting · Russian Federation | 4 | Completed | Novartis | Jun 2013 | 298 |
| NCT01498887Multiple Sclerosis, Relapsing-Remitting · Australia, Spain | 4 | Completed | Novartis | Dec 26, 2015 | 347 |
| NCT01497262Multiple Sclerosis · Argentina, Brazil, Colombia and more | 3 | Completed | Novartis | Apr 2014 | 162 |
| NCT01499667Multiple Sclerosis, Relapsing-Remitting · Australia, Austria, Czech Republic and more | 3 | Terminated | Novartis | Nov 2012 | 142 |
| NCT01420055Multiple Sclerosis, Relapsing-Remitting · France | 4 | Completed | Novartis | Jun 2013 | 189 |
| NCT01333501Multiple Sclerosis · Germany, Italy | 4 | Completed | Novartis | Sep 2015 | 151 |
| NCT01317004Multiple Sclerosis, Relapsing-Remitting · Italy | 4 | Completed | Novartis | Jun 2014 | 61 |
| NCT01310166Multiple Sclerosis, Relapsing-Remitting · Germany | 4 | Completed | Novartis | Jul 2012 | 447 |
| NCT01201356Multiple Sclerosis · United States, Argentina, Australia and more | 3 | Completed | Novartis | Oct 19, 2018 | 4,125 |
| NCT01199861Relapsing Multiple Sclerosis · Belgium, Canada, Finland and more | 3 | Completed | Novartis | May 2011 | 138 |
| NCT01216072Relapsing Forms of Multiple Sclerosis · United States, Canada, Puerto Rico | 4 | Completed | Novartis | Aug 2012 | 1,053 |
| NCT01127750Relapsing Multiple Sclerosis · Australia, Austria, Belgium and more | 3 | Completed | Novartis | Oct 2011 | 2,417 |
| NCT00785083Asthma · United Kingdom | 2 | Completed | Novartis | Feb 2009 | 36 |
| NCT00731692Multiple Sclerosis, Chronic Progressive · United States, Australia, Belgium and more | 3 | Terminated | Novartis | Jun 22, 2015 | 970 |
| NCT00731523Renal Insufficiency · Russian Federation | 1 | Completed | Novartis | Aug 2008 | 18 |
| NCT00670449Multiple Sclerosis · Japan | 2 | Completed | Novartis | Apr 2012 | 143 |
| NCT00662649Multiple Sclerosis · Australia, Belgium, Canada and more | 3 | Completed | Novartis | Jun 2011 | 920 |
| NCT00537082Multiple Sclerosis · Japan | 2 | Completed | Novartis | Feb 2010 | 171 |
| NCT00416845Healthy · United States | 1 | Completed | Novartis | Mar 2007 | 39 |
| NCT00355134Multiple Sclerosis · United States, Australia, Austria and more | 3 | Completed | Novartis | Jun 2011 | 1,083 |
| NCT00340834Multiple Sclerosis · United States, Argentina, Australia and more | 3 | Completed | Novartis | Jul 2011 | 1,292 |
| NCT00333138Multiple Sclerosis · Canada, Denmark, Finland and more | 2 | Completed | Novartis | Apr 2011 | 281 |
| NCT00289978Multiple Sclerosis, Relapsing-Remitting · Australia, Belgium, Canada and more | 3 | Completed | Novartis | Jul 2009 | 1,272 |
| NCT00239902Renal Transplantation | 2 | Completed | Novartis | Nov 2004 | 396 |
| NCT00239876Renal Transplantation | 3 | Completed | Novartis | Dec 2005 | 140 |
| NCT00239863Renal Transplantation | 3 | Completed | Novartis | May 2006 | 684 |
| NCT00239811Renal Transplantation | 3 | Completed | Novartis | May 2006 | 684 |
| NCT00239798Renal Transplantation | 2 | Completed | Novartis | Nov 2006 | 255 |
| NCT00239785Renal Transplantation | 3 | Completed | Novartis | Apr 2005 | 684 |
| NCT00099801Rejection, Psychology | 3 | Completed | Novartis | Mar 2006 | |
| NCT00099749Rejection, Psychology · United States | 3 | Completed | Novartis | Apr 2006 | 255 |
| NCT00099736Rejection, Psychology · United States | 3 | Completed | Novartis | Sep 19, 2005 | 696 |
| NCT00098735Rejection, Psychology | 3 | Completed | Novartis | Apr 2006 | 140 |
How it is read
Names in the registry
- “Fingolimod”, 22 entries
- “FTY720”, 16 entries
- “Fingolimod 0.5 mg”, 4 entries
- “fingolimod”, 4 entries
- “Fingolimod 1.25 mg”, 3 entries
Conditions, from the studies’ own filings
- Multiple Sclerosis, 20 studies
- Multiple Sclerosis, Relapsing-Remitting, 15 studies
- Renal Insufficiency, 1 study
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, 1 study
- Multiple Sclerosis, Chronic Progressive, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.